David Ozretić

David Ozretić

Auto-generated profile, based on publicly available information

David Ozretić

Department of Diagnostic and Interventional Neuroradiology, University Hospital Centre Zagreb, Zagreb, Croatia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
RNRaul G. Nogueira
Raul G. Nogueira
MQMuhammad M. Qureshi
Muhammad M. Qureshi
MAMohamad Abdalkader
Mohamad Abdalkader
SMSheila Ouriques Martins
Sheila Ouriques Martins
HYHiroshi Yamagami
Hiroshi Yamagami
ORon behalf of the SVIN COVID-19 Global Stroke Registry
on behalf of the SVIN COVID-19 Global Stroke Registry
Objective To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods. Methods We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 91,373 stroke admissions in the 4 months immediately before compared to 80,894 admissions during the pandemic months, representing an 11.5% (95% confidence interval [CI] −11.7 to −11.3, p < 0.0001) decline. There were 13,334 IVT therapies in the 4 months preceding compared to 11,570 procedures during the pandemic, representing a 13.2% (95% CI −13.8 to −12.7, p < 0.0001) drop. Interfacility IVT transfers decreased from 1,337 to 1,178, or an 11.9% decrease (95% CI −13.7 to −10.3, p = 0.001). Recovery of stroke hospitalization volume (9.5%, 95% CI 9.2–9.8, p < 0.0001) was noted over the 2 later (May, June) vs the 2 earlier (March, April) pandemic months. There was a 1.48% stroke rate across 119,967 COVID-19 hospitalizations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was noted in 3.3% (1,722/52,026) of all stroke admissions. Conclusions The COVID-19 pandemic was associated with a global decline in the volume of stroke hospitalizations, IVT, and interfacility IVT transfers. Primary stroke centers and centers with higher COVID-19 inpatient volumes experienced steeper declines. Recovery of stroke hospitalization was noted in the later pandemic months.

1 August 2021 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
ZPZ. Poljakovic
Z. Poljakovic
SSS. Supe
S. Supe
JLJ. Ljevak
J. Ljevak
KSK. Starcevic
K. Starcevic
IPIvan Peric
Ivan Peric
DOD. Ozretic
D. Ozretic

1 August 2011 in Croatian Medical Journal
Verified
Journal Article
Open access
ZSZlatko Sabol
Zlatko Sabol
BRBiserka Rešić
Biserka Rešić
RJRomana Gjergja Juraški
Romana Gjergja Juraški
FSFilip Sabol
Filip Sabol
MŠMatilda Kovač Šižgorić
Matilda Kovač Šižgorić
DŠDubravka Šepić-Grahovac
Dubravka Šepić-Grahovac
To determine the prevalence, number, and location of multiple (≥2) T2-hyperintensities on brain magnetic resonance imaging (MRI) in children with neurofibromatosis type 1 (NF1) and their correlation with age, and to establish their sensitivity, specificity, and accuracy for the diagnosis of NF1 in children, especially in the early age (2-7 years). We performed a cross-sectional study of 162 patients with NF1 from Croatian Neurofibromatosis Association Database and 163 control children between the ages of 2 and 18 years who underwent brain MRI between 1989 and 2009. Multiple T2-hyperintensities were present in 74% of NF1 patients and 1.8% of controls. They were mainly located in the basal ganglia, brainstem, and cerebellum and were significantly decreased in prevalence and number in the older age. T2-hyperintensities had excellent diagnostic accuracy with the area under the receiver operating characteristic (ROC) curve of 0.849 and 95% confidence interval (CI) of 0.805-0.886. The diagnostic sensitivity, specificity, and accuracy rate of T2-hyperintensities for NF1 were highest in the youngest age (2-7 years): 81% (95% CI 71%-89.1%), 99% (95% CI 92.3%-100%), and 85.8 (95% CI 83.3-93.8), respectively. This study strongly suggests the inclusion of T2-hyperintensities on brain MRI on the list of diagnostic criteria for NF1, especially in children of early age, when the clinical penetration of the NF1 gene has not yet been completely finished.


5 March 2017 in Case Reports in Endocrinology
Verified
Journal Article
Open access
PDF file
AKAna Mišir Krpan
Ana Mišir Krpan
TDTina Dusek
Tina Dusek
ZRZoran Rakusic
Zoran Rakusic
MSMirsala Solak
Mirsala Solak
IKIvana Kraljević
Ivana Kraljević
DKDarko Kastelan
Darko Kastelan
Background and Importance. In the last eight years temozolomide (TMZ) has been used as the last-line treatment modality for aggressive pituitary tumors to be applied after the failure of surgery, medical therapy, and radiotherapy. The objective was to achieve a rapid control of tumor growth and hormone normalization with concurrent chemoradiotherapy in a patient with very aggressive ACTH pituitary adenoma. Clinical Presentation. We describe a patient with an aggressive ACTH-producing adenoma treated with concurrent temozolomide and radiotherapy. The patient suffered from an aggressive ACTH adenoma resistant to surgical and medical treatment. After two months of concurrent temozolomide and radiotherapy, cortisol normalization and significant tumor shrinkage were observed. After 22 months of follow-up, there is still no evidence of tumor recurrence. Conclusion. Concurrent treatment with temozolomide and irradiation appears to be highly effective in the achievement of the tumor volume control as well as in the control of ACTH secretion in aggressive ACTH adenoma.

15 June 2021 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
IJIvan Jovanović
Ivan Jovanović
JNJakob Nemir
Jakob Nemir
DGDanilo Gardijan
Danilo Gardijan
Milan MiloševićMilan Milošević
Milan Milošević
ZPZdravka Poljaković
Zdravka Poljaković
MRMarko Radoš
Marko Radoš